查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007859

人工智慧临床试验平台市场预测至2034年—按平台类型、部署模式、技术、应用、最终用户和地区分類的全球分析

AI Clinical Trial Platforms Market Forecasts to 2034 - Global Analysis By Platform Type, Deployment Mode, Technology, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球 AI 临床试验平台市场规模将达到 34 亿美元，并在预测期内以 23.8% 的复合年增长率增长，到 2034 年将达到 188 亿美元。

人工智慧临床试验平台是指利用机器学习、预测建模、自然语言处理和真实世界数据分析来优化药品和医疗设备临床试验的设计、执行、监测和监管申报的软体系统。这些平台可自动完成受试者招募和合格筛检、自适应试验通讯协定设计、安全讯号检测、临床实验绩效管理以及资料完整性检验。其主要功能包括与电子资料收集 (EDC) 系统整合、支援分散式临床实验、基于生物标记的患者分层以及生成新药研究申请 (IND) 和新药认证协议 (NDA) 申报所需的监管文件。

加速药物研发并简化研究对象的招募流程

人工智慧临床试验平台正在加速药物创新週期，协助全球药物研发管线更快完成药物开发，并提高受试者招募效率。先进的机器学习演算法简化了受试者识别、研究中心选择和通讯协定优化流程，显着缩短了临床实验週期。临床试验赞助者方正日益利用即时数据分析优化决策，提高临床实验成功率。自动化程度的提高最大限度地减少了人工干预和操作延迟。因此，人工智慧的整合正在变革临床工作流程，在临床实验激烈的市场环境中提高效率，同时降低整体研发成本。

资料隐私和监管合规问题

由于GDPR和HIPAA等严格的法规结构，资料隐私合规的复杂性成为人工智慧临床试验平台市场的主要阻碍因素。跨司法管辖区管理敏感的患者资料会增加营运负担和合规成本。资料保护法律的区域差异也使跨境临床研究和资料共用更加复杂。此外，确保资料储存安全、匿名化和知情同意管理需要复杂的基础设施，这限制了可扩展性，并减缓了人工智慧驱动的临床试验解决方案在全球范围内的普及。

利用预测分析提高测试设计的效率

人工智慧临床试验平台为简化试验设计开启了新的可能性。这些平台能够实现精准的患者分层、风险评估和结果预测，进而提高试验的准确性。製药公司正越来越多地采用人工智慧驱动的模拟技术来设计自适应和分散式试验。这种转变有助于提高患者参与度并降低脱落率。此外，与真实世界资料来源的整合能够增强临床洞察力。随着对个人化医疗需求的不断增长，预测能力有望显着推动平台应用和市场成长。

影响测试结果可靠性的演算法偏差

演算法偏差会影响试验结果的可靠性，对市场信誉构成重大威胁。基于有限或不具代表性的资料集训练的人工智慧模型可能产生偏差的结果，从而损害试验的完整性。这导致监管机构、申办者和患者对人工智慧产生的结论的有效性日益担忧。此外，人工智慧调查方法缺乏标准化进一步加剧了这些风险。负面结果可能导致更严格的审查和核准延迟。因此，解决偏差问题并确保资料多样性对于维护信任和保障市场的长期发展至关重要。

新冠疫情的影响：

在新冠疫情对传统临床试验营运造成衝击的同时，也显着加速了人工智慧驱动的临床试验平台的普及应用。封锁措施和对医疗设施的限制使得分散式和虚拟试验模式成为必需，也因此更加依赖人工智慧工具。病患招募、监测和资料收集等流程透过数位化解决方案得以简化。製药公司迅速采用远端技术以维持试验的连续性。这种转变提高了营运效率，并减少了对实体基础设施的依赖。因此，疫情起到了催化剂的作用，永久地将临床试验调查方法转变为一个由人工智慧驱动的生态系统。

在预测期内，患者招募平台细分市场预计将成为最大的细分市场。

预计在预测期内，患者招募平台细分市场将占据最大的市场份额。患者入组流程日益复杂是推动此细分市场成长的主要因素。人工智慧工具能够透过先进的数据分析和电子健康记录，精准识别合格的受试者，从而显着降低招募时间和成本。製药公司优先考虑高效率的入组流程，以避免试验延误和经济损失。此外，更精准的患者配对能够提高试验的成功率。因此，对简化招募流程日益增长的需求正在推动该细分市场占据领先的市场份额。

在预测期内，基于云端的细分市场预计将呈现最高的复合年增长率。

在预测期内，受对可扩展、灵活解决方案日益增长的需求驱动，云端解决方案预计将呈现最高的成长率。云端技术的应用能够实现即时数据存取、无缝协作和经济高效的基础设施管理。企业可以受益于更强大的资料储存能力和更快的处理速度。此外，云端平台支援分散式测试和远端监控，符合不断发展的行业趋势。云端安全技术的持续进步也进一步推动了云端技术的普及。随着数位转型的加速，云端解决方案可望大幅扩大市场规模。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的医疗保健基础设施和大型製药企业的强大影响力。对研发的大量投入，以及对人工智慧技术的早期应用，巩固了其市场主导地位。有利的法规环境和充足的专业人才资源也进一步推动了市场成长。此外，电子健康记录的广泛应用也实现了高效率的数据整合。这些因素共同作用，使北美成为领先的区域市场。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗基础设施的快速扩张和临床试验活动的日益活跃。中国和印度等新兴经济体正在对数位医疗技术进行大量投资。不断增长的患者群体和多样化的数据集为人工智慧的应用提供了强劲的机会。此外，政府的支持性措施和成本优势也吸引全球製药公司。这种充满活力的环境正在加速市场成长，并将亚太地区打造为一个极具潜力的地区。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球人工智慧临床试验平台市场：按平台类型划分

  • 病患招募平台
  • 测试设计平台
  • 资料管理平台
  • 临床分析平台
  • 远端监控平台
  • 网站管理平台
  • 其他平台类型

第六章 全球人工智慧临床试验平台市场：依部署模式划分

  • 基于云端的
  • 现场
  • 杂交种
  • SaaS平台
  • 网路为基础的平台
  • 整合平台

第七章 全球人工智慧临床试验平台市场：按技术划分

  • 机器学习
  • 深度学习
  • 自然语言处理
  • 预测分析
  • 巨量资料分析
  • 云端运算
  • 其他技术

第八章 全球人工智慧临床试验平台市场：按应用领域划分

  • 肿瘤临床试验
  • 心臟病学领域的临床试验
  • 神经病学领域的临床试验
  • 感染疾病临床试验
  • 罕见疾病临床试验
  • 免疫学检查
  • 其他用途

第九章 全球人工智慧临床试验平台市场：按最终用户划分

  • 製药公司
  • 生技公司
  • 受託研究机构（CRO）
  • 学术机构
  • 医院
  • 政府机构
  • 其他最终用户

第十章 全球人工智慧临床试验平台市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Astellas Pharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Vericel Corporation
  • Mesoblast Limited
  • Organogenesis Holdings Inc.
  • Bluebird Bio, Inc.
  • Sangamo Therapeutics
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Intellia Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Amgen Inc.
Product Code: SMRC34768

According to Stratistics MRC, the Global AI Clinical Trial Platforms Market is accounted for $3.4 billion in 2026 and is expected to reach $18.8 billion by 2034 growing at a CAGR of 23.8% during the forecast period. AI clinical trial platforms refer to software systems leveraging machine learning, predictive modeling, natural language processing, and real-world data analytics to optimize the design, execution, monitoring, and regulatory submission of pharmaceutical and medical device clinical trials. They automate patient recruitment and eligibility screening, adaptive trial protocol design, safety signal detection, site performance management, and data integrity verification. Key capabilities include electronic data capture integration, decentralized trial support, biomarker-driven patient stratification, and regulatory document generation for IND and NDA submission packages.

Market Dynamics:

Driver:

Faster drug development and recruitment efficiency

Accelerating pharmaceutical innovation cycles, AI clinical trial platforms are enabling faster drug development and recruitment efficiency across global pipelines. Advanced machine learning algorithms streamline patient identification, site selection, and protocol optimization, significantly reducing trial timelines. Sponsors are increasingly leveraging real-time data analytics to enhance decision-making and improve trial success rates. This growing reliance on automation minimizes manual intervention and operational delays. Consequently, the integration of AI is transforming clinical workflows, improving productivity while reducing overall development costs in a competitive landscape.

Restraint:

Data privacy and regulatory compliance issues

Data privacy compliance complexity poses a significant restraint in the AI clinical trial platforms market, driven by stringent regulatory frameworks such as GDPR and HIPAA. Managing sensitive patient data across jurisdictions increases operational burdens and compliance costs. Variability in regional data protection laws complicates cross-border clinical research and data sharing. Additionally, ensuring secure data storage, anonymization, and consent management requires advanced infrastructure, thereby limiting scalability and slowing adoption of AI-driven clinical trial solutions globally.

Opportunity:

Predictive analytics enhancing trial design efficiency

AI clinical trial platforms are unlocking new opportunities in optimizing trial design efficiency. These platforms enable accurate patient stratification, risk assessment, and outcome prediction, enhancing trial precision. Pharmaceutical companies are increasingly adopting AI-driven simulations to design adaptive and decentralized trials. This shift improves patient engagement and reduces dropout rates. Additionally, integration with real-world data sources enhances clinical insights. As demand for personalized medicine rises, predictive capabilities are expected to significantly boost platform adoption and market growth.

Threat:

Algorithm bias impacting trial outcome reliability

Algorithm bias impacting trial outcome reliability poses a critical threat to market credibility. AI models trained on limited or non-representative datasets may produce skewed results, affecting trial integrity. This raises concerns among regulators, sponsors, and patients regarding the validity of AI-driven conclusions. Additionally, lack of standardization in AI methodologies further amplifies these risks. Negative outcomes could lead to increased scrutiny and delayed approvals. Consequently, addressing bias and ensuring data diversity remain essential to sustaining trust and long-term market viability.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated the adoption of AI clinical trial platforms as traditional trial operations faced disruptions. Lockdowns and restricted site access necessitated decentralized and virtual trial models, increasing reliance on AI-driven tools. Patient recruitment, monitoring, and data collection were streamlined through digital solutions. Pharmaceutical companies rapidly embraced remote technologies to maintain trial continuity. This shift enhanced operational efficiency and reduced dependency on physical infrastructure. As a result, the pandemic acted as a catalyst, permanently transforming clinical trial methodologies toward AI-enabled ecosystems.

The patient recruitment platforms segment is expected to be the largest during the forecast period

The patient recruitment platforms segment is expected to account for the largest market share during the forecast period, due to the increasing complexity of patient enrollment processes, the patient recruitment platforms segment is expected to dominate the market. AI-powered tools enable precise identification of eligible participants through advanced data analytics and electronic health records. This significantly reduces recruitment timelines and costs. Pharmaceutical companies prioritize efficient enrollment to avoid trial delays and financial losses. Additionally, improved patient matching enhances trial success rates. Consequently, the growing need for streamlined recruitment processes is reinforcing the segment's leading market share.

The cloud-based segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cloud-based segment is predicted to witness the highest growth rate, driven by the rising demand for scalable and flexible solutions, the cloud-based segment is projected to witness the highest growth rate. Cloud deployment enables real-time data access, seamless collaboration, and cost-effective infrastructure management. Organizations benefit from enhanced data storage capabilities and faster processing speeds. Additionally, cloud platforms support decentralized trials and remote monitoring, aligning with evolving industry trends. Continuous advancements in cloud security further strengthen adoption. As digital transformation accelerates, cloud-based solutions are expected to drive significant market expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its advanced healthcare infrastructure and strong presence of leading pharmaceutical companies. High investment in research and development, coupled with early adoption of AI technologies, supports market dominance. Favorable regulatory frameworks and availability of skilled professionals further enhance growth. Additionally, widespread use of electronic health records enables efficient data integration. These factors collectively position North America as the leading regional market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly expanding healthcare infrastructure and increasing clinical trial activities. Emerging economies such as China and India are investing heavily in digital health technologies. Growing patient populations and diverse datasets provide strong opportunities for AI adoption. Additionally, supportive government initiatives and cost advantages attract global pharmaceutical companies. This dynamic environment is accelerating market growth, positioning Asia Pacific as a high-potential region.

Key players in the market

Some of the key players in AI Clinical Trial Platforms Market include Astellas Pharma Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Johnson & Johnson, Vericel Corporation, Mesoblast Limited, Organogenesis Holdings Inc., Bluebird Bio, Inc., Sangamo Therapeutics, CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc..

Key Developments:

In March 2026, Novartis AG announced implementation of an AI clinical trial monitoring platform across 150 active studies reducing on-site monitoring visits through risk-based analytics.

In February 2026, Takeda Pharmaceutical Company Limited expanded its AI clinical operations platform partnership to optimize adaptive trial design and real-world evidence integration across rare disease programs.

In January 2026, Pfizer Inc. deployed an AI-powered patient recruitment and eligibility screening platform across its global Phase III oncology trial portfolio to accelerate enrollment timelines.

In November 2025, Roche Holding AG launched a decentralized trial AI management platform enabling remote patient data collection for its neurology and oncology Phase II and III programs.

Platform Types Covered:

  • Carbon Management Tools
  • Energy Optimization Tools
  • Waste Management Tools
  • Supply Chain Sustainability Tools
  • ESG Analytics Platforms
  • Climate Risk Modeling Tools
  • Other Tool Types

Deployment Modes Covered:

  • Cloud-based
  • On-premise
  • Hybrid
  • SaaS Platforms
  • Web-based Platforms
  • Integrated Platforms

Technologies Covered:

  • Machine Learning
  • Deep Learning
  • Natural Language Processing
  • Predictive Analytics
  • Big Data Analytics
  • Cloud Computing
  • Other Technologies

Applications Covered:

  • Oncology Trials
  • Cardiology Trials
  • Neurology Trials
  • Infectious Disease Trials
  • Rare Disease Trials
  • Immunology Trials
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Contract Research Organizations (CROs)
  • Academic Institutes
  • Hospitals
  • Government Organizations
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI Clinical Trial Platforms Market, By Platform Type

  • 5.1 Patient Recruitment Platforms
  • 5.2 Trial Design Platforms
  • 5.3 Data Management Platforms
  • 5.4 Clinical Analytics Platforms
  • 5.5 Remote Monitoring Platforms
  • 5.6 Site Management Platforms
  • 5.7 Other Platform Types

6 Global AI Clinical Trial Platforms Market, By Deployment Mode

  • 6.1 Cloud-based
  • 6.2 On-premise
  • 6.3 Hybrid
  • 7.4 SaaS Platforms
  • 7.5 Web-based Platforms
  • 7.6 Integrated Platforms

7 Global AI Clinical Trial Platforms Market, By Technology

  • 7.1 Machine Learning
  • 7.2 Deep Learning
  • 7.3 Natural Language Processing
  • 7.4 Predictive Analytics
  • 7.5 Big Data Analytics
  • 7.6 Cloud Computing
  • 7.7 Other Technologies

8 Global AI Clinical Trial Platforms Market, By Application

  • 8.1 Oncology Trials
  • 8.2 Cardiology Trials
  • 8.3 Neurology Trials
  • 8.4 Infectious Disease Trials
  • 8.5 Rare Disease Trials
  • 8.6 Immunology Trials
  • 8.7 Other Applications

9 Global AI Clinical Trial Platforms Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Biotechnology Firms
  • 9.3 Contract Research Organizations (CROs)
  • 9.4 Academic Institutes
  • 9.5 Hospitals
  • 9.6 Government Organizations
  • 9.7 Other End Users

10 Global AI Clinical Trial Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Astellas Pharma Inc.
  • 13.2 Novartis AG
  • 13.3 Pfizer Inc.
  • 13.4 Roche Holding AG
  • 13.5 Johnson & Johnson
  • 13.6 Vericel Corporation
  • 13.7 Mesoblast Limited
  • 13.8 Organogenesis Holdings Inc.
  • 13.9 Bluebird Bio, Inc.
  • 13.10 Sangamo Therapeutics
  • 13.11 CRISPR Therapeutics AG
  • 13.12 Editas Medicine
  • 13.13 Intellia Therapeutics
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Bristol-Myers Squibb Company
  • 13.16 AbbVie Inc.
  • 13.17 Gilead Sciences, Inc.
  • 13.18 Amgen Inc.

List of Tables

  • Table 1 Global AI Clinical Trial Platforms Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global AI Clinical Trial Platforms Market Outlook, By Platform Type (2023-2034)($MN)
  • Table 3 Global AI Clinical Trial Platforms Market Outlook, By Patient Recruitment Platforms (2023-2034)($MN)
  • Table 4 Global AI Clinical Trial Platforms Market Outlook, By Trial Design Platforms (2023-2034)($MN)
  • Table 5 Global AI Clinical Trial Platforms Market Outlook, By Data Management Platforms (2023-2034)($MN)
  • Table 6 Global AI Clinical Trial Platforms Market Outlook, By Clinical Analytics Platforms (2023-2034)($MN)
  • Table 7 Global AI Clinical Trial Platforms Market Outlook, By Remote Monitoring Platforms (2023-2034)($MN)
  • Table 8 Global AI Clinical Trial Platforms Market Outlook, By Site Management Platforms (2023-2034)($MN)
  • Table 9 Global AI Clinical Trial Platforms Market Outlook, By Other Platform Types (2023-2034)($MN)
  • Table 10 Global AI Clinical Trial Platforms Market Outlook, By Deployment Mode (2023-2034)($MN)
  • Table 11 Global AI Clinical Trial Platforms Market Outlook, By Cloud-based (2023-2034)($MN)
  • Table 12 Global AI Clinical Trial Platforms Market Outlook, By On-premise (2023-2034)($MN)
  • Table 13 Global AI Clinical Trial Platforms Market Outlook, By Hybrid (2023-2034)($MN)
  • Table 14 Global AI Clinical Trial Platforms Market Outlook, By SaaS Platforms (2023-2034)($MN)
  • Table 15 Global AI Clinical Trial Platforms Market Outlook, By Web-based Platforms (2023-2034)($MN)
  • Table 16 Global AI Clinical Trial Platforms Market Outlook, By Integrated Platforms (2023-2034)($MN)
  • Table 17 Global AI Clinical Trial Platforms Market Outlook, By Technology (2023-2034)($MN)
  • Table 18 Global AI Clinical Trial Platforms Market Outlook, By Machine Learning (2023-2034)($MN)
  • Table 19 Global AI Clinical Trial Platforms Market Outlook, By Deep Learning (2023-2034)($MN)
  • Table 20 Global AI Clinical Trial Platforms Market Outlook, By Natural Language Processing (2023-2034)($MN)
  • Table 21 Global AI Clinical Trial Platforms Market Outlook, By Predictive Analytics (2023-2034)($MN)
  • Table 22 Global AI Clinical Trial Platforms Market Outlook, By Big Data Analytics (2023-2034)($MN)
  • Table 23 Global AI Clinical Trial Platforms Market Outlook, By Cloud Computing (2023-2034)($MN)
  • Table 24 Global AI Clinical Trial Platforms Market Outlook, By Other Technologies (2023-2034)($MN)
  • Table 25 Global AI Clinical Trial Platforms Market Outlook, By Application (2023-2034)($MN)
  • Table 26 Global AI Clinical Trial Platforms Market Outlook, By Oncology Trials (2023-2034)($MN)
  • Table 27 Global AI Clinical Trial Platforms Market Outlook, By Cardiology Trials (2023-2034)($MN)
  • Table 28 Global AI Clinical Trial Platforms Market Outlook, By Neurology Trials (2023-2034)($MN)
  • Table 29 Global AI Clinical Trial Platforms Market Outlook, By Infectious Disease Trials (2023-2034)($MN)
  • Table 30 Global AI Clinical Trial Platforms Market Outlook, By Rare Disease Trials (2023-2034)($MN)
  • Table 31 Global AI Clinical Trial Platforms Market Outlook, By Immunology Trials (2023-2034)($MN)
  • Table 32 Global AI Clinical Trial Platforms Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 33 Global AI Clinical Trial Platforms Market Outlook, By End User (2023-2034)($MN)
  • Table 34 Global AI Clinical Trial Platforms Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 35 Global AI Clinical Trial Platforms Market Outlook, By Biotechnology Firms (2023-2034)($MN)
  • Table 36 Global AI Clinical Trial Platforms Market Outlook, By Contract Research Organizations (CROs) (2023-2034)($MN)
  • Table 37 Global AI Clinical Trial Platforms Market Outlook, By Academic Institutes (2023-2034)($MN)
  • Table 38 Global AI Clinical Trial Platforms Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 39 Global AI Clinical Trial Platforms Market Outlook, By Government Organizations (2023-2034)($MN)
  • Table 40 Global AI Clinical Trial Platforms Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.